Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models

Goméz-López, Sandra; Whiteman, Zoe E; Janes, Sam M.

doi:10.1038/s42003-021-02470-x

Cited by 9 publications

(5 citation statements)

References 130 publications

(214 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To conclude, this helpful study adds considerably to our relatively limited knowledge of lung preneoplasia, strongly reinforces smoking cessation benefits, speaks against low value medical interventions that do not improve health outcomes and spurs research efforts [36] in order to harness modern "omics" and advanced bronchoscopy to enable more effective screening, detection and secondary prevention strategies for this terrible disease. Much more is needed than meets the eye.…”

mentioning

confidence: 67%

More than meets the eye

et al. 2022

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 67%

More than meets the eye

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As a major subtype of non-small cell lung cancer (NSCLC), lung squamous cell carcinoma occurs proximal to the lung and originates primarily from bronchial basal cells. 11 Unlike lung adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefited from targeted therapies. 12 Diagnosis is often challenging, particularly in small biopsy specimens.…”

Section: Discussionmentioning

confidence: 99%

miR-139-5p and miR-451a as a Diagnostic Biomarker in LUSC

Gao¹,

Li²,

Song³

et al. 2023

PGPM

View full text Add to dashboard Cite

Background Lung squamous cell carcinoma (LUSC) is a type of lung cancer that originates from segmental or subsegmental bronchial mucosa. There is evidence that miRNA plays an important role in the occurrence and progression of tumors. Methods In this study, plasma samples of patients with early LUSC and healthy volunteers were subjected to miRNA sequencing, and the levels of differentially expressed miRNAs (DEMs) in LUSC tissues were analyzed using R language. Cox regression and Kaplan–Meier (K-M) survival curve analyses were performed to determine the relationship between DEMs and prognosis in LUSC, and PCR method was verified for the plasma expression level of DEMs in patients with LUSC. The levels of CYFRA21-1 and SCC-Ag in plasma were measured, and area under curve (AUC) was used to evaluate the diagnostic value of the DEMs. Results A total of 21 DEMs were screened out by sequencing. The expression levels of DEMs in tissue samples in the TCGA database were analyzed, and four DEMs with consistent expression levels were further screened from plasma and tissue samples. Regression analysis and K-M curve were performed to select two DEMs (miR-139-5p, miR-451a) that were correlated with the prognosis. PCR verification results showed that the levels of miR-451a and miR-139-5p were low in patients, and the level of miR-139-5p in late stages III & IV with the patients of LUSC was higher than that in stages I & II. The AUC values of the four indicators (SCC-Ag, CYFRA21-1, miR-451a and miR-139-5p) in the diagnosis of LUSC, early and late cases were 0.884, 0.935 and 0.778, respectively. Conclusion The detection of miR-139-5p and miR-451a levels in plasma has a certain potential in the non-invasive diagnosis, especially in patients with early stages of LUSC.

show abstract

“…The feasibility of using micro-CT for imaging squamous cell lung cancer models has not been assessed using this protocol due to the lack of well characterised in vivo mouse models. It is useful to note that the majority of autochthonous murine models of lung cancer display a mixture of adenocarcinoma and squamous cell carcinoma [53][54][55][56] , our CT imaging protocol cannot conclusively disambiguate between the two.…”

Section: Limitationsmentioning

confidence: 99%